Zynerba Pharma (ZYNE) Tops Q4 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Zynerba Pharma (ZYNE) Tops Q4 EPS by 21c

Zynerba Pharma (ZYNE) Commences Phase 2 Trial of Zygel in Autism Spectrum Disorder

March 7, 2019 7:09 AM EST

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) today announced that it has initiated the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial. The trial will assess the safety, tolerability and efficacy of Zygel (previously referred to as ZYN002) for the treatment of child and adolescent patients with Autism Spectrum Disorder (ASD). The Company expects to present topline data from this study in the... More